替奈普酶与阿替普酶在缺血性卒中发病4·5小时内经灌注影像筛选患者中的溶栓比较(TASTE):一项多中心、随机、对照、3期非劣效性试验
TASTE是一项国际多中心、开放标签、随机、3期非劣效性试验,在8个国家35家医院纳入发病4·5小时内、经脑灌注影像目标不匹配标准筛选且不考虑血管内取栓的缺血性卒中患者,1:1随机接受静脉替奈普酶0·25 mg/kg或阿替普酶0·90 mg/kg。主要结局为3个月无残疾(改良Rankin量表0-1分)比例。意向治疗分析中替奈普酶组191/335(57%)vs 阿替普酶组188/340(55%),标准化风险差0·03(95%CI -0·033至0·10),单侧非劣效P=0·031;符合方案集分析中173/295(59%)vs 171/306(56%),标准化风险差0·05(95%CI -0·02至0·12),单侧非劣效P=0·01。
要点
- 意向治疗分析达到非劣效:替奈普酶组57% vs 阿替普酶组55%无残疾,标准化风险差0·03(95%CI -0·033至0·10)。
- 符合方案集分析亦达非劣效:替奈普酶组59% vs 阿替普酶组56%,标准化风险差0·05(95%CI -0·02至0·12)。
- 症状性颅内出血替奈普酶组9/337(3%)vs 阿替普酶组6/340(2%),未经调整风险差0·01(95%CI -0·01至0·03)。
核心结论
- 研究结果进一步支持替奈普酶对阿替普酶的非劣效性,尤其是在使用灌注影像筛选适合再灌注的卒中患者时。
- 符合方案集分析达到非劣效,但意向治疗分析未达到,可能归因于样本量限制。
- 使用灌注CT辅助筛选早期时间窗内静脉溶栓患者的大规模实施被证明可行。
研究设计与样本
- 国际、多中心、开放标签、平行组、随机、临床非劣效性试验,纳入8个国家35家医院的患者。
- 纳入年龄18岁及以上、缺血性卒中发病或最后确认正常4·5小时内、不考虑血管内取栓、且脑灌注影像符合目标不匹配标准的患者。
- 通过中心化网络服务器按随机置换区组1:1随机分配至静脉替奈普酶0·25 mg/kg或阿替普酶0·90 mg/kg。
- 计划招募832例,以90%把握度(单侧α=0·025)检测0·08的风险差,绝对非劣效界值为-0·03。
- 2014年3月21日至2023年10月20日共纳入680例,随机分配至替奈普酶组339例与阿替普酶组341例,均纳入意向治疗分析。
主要发现
- 意向治疗分析中主要结局发生于替奈普酶组191/335(57%)vs 阿替普酶组188/340(55%),标准化风险差0·03(95%CI -0·033至0·10),单侧非劣效P=0·031。
- 符合方案集分析中主要结局发生于替奈普酶组173/295(59%)vs 阿替普酶组171/306(56%),标准化风险差0·05(95%CI -0·02至0·12),单侧非劣效P=0·01。
- 症状性颅内出血替奈普酶组9/337(3%)vs 阿替普酶组6/340(2%),未经调整风险差0·01(95%CI -0·01至0·03)。
- 开始治疗后90天内死亡替奈普酶组23/335(7%)vs 阿替普酶组15/340(4%),标准化风险差0·02(95%CI -0·02至0·05)。
- 患者中位年龄74岁(IQR 63-82),基线美国国立卫生研究院卒中量表评分7分(4-11),女性260例(38%)。
关键数值与推荐
- 主要结局为3个月无残疾(改良Rankin量表0-1分)的患者比例,经盲法评估,在意向治疗和符合方案集人群中分析。
- 非劣效界值为绝对风险差-0·03,单侧α=0·025。
- 意向治疗分析替奈普酶组191/335(57%)vs 阿替普酶组188/340(55%),标准化风险差0·03(95%CI -0·033至0·10),单侧非劣效P=0·031。
- 符合方案集分析替奈普酶组173/295(59%)vs 阿替普酶组171/306(56%),标准化风险差0·05(95%CI -0·02至0·12),单侧非劣效P=0·01。
临床怎么用
- 作者认为,研究结果进一步支持替奈普酶对阿替普酶的非劣效性,尤其是在使用灌注影像筛选适合再灌注的卒中患者时。
- 作者指出,使用灌注CT辅助筛选早期时间窗内静脉溶栓患者的大规模实施被证明可行。
局限性
- 招募在其他试验结果公布显示替奈普酶对阿替普酶非劣效后提前终止。
- 意向治疗分析中5例患者主要结局数据缺失,采用多重插补处理。
- 74例发生方案违背,符合方案集人群为601例(替奈普酶组295例、阿替普酶组306例)。
- 意向治疗分析未达到非劣效,作者认为可能归因于样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous tenecteplase increases reperfusion in patients with salvageable brain tissue on perfusion imaging and might have advantages over alteplase as a thrombolytic for ischaemic stroke. We aimed to assess the non-inferiority of tenecteplase versus alteplase on clinical outcomes in patients selected by use of perfusion imaging. METHODS: This international, multicentre, open-label, parallel-group, randomised, clinical non-inferiority trial enrolled patients from 35 hospitals in eight countries. Participants were aged 18 years or older, within 4·5 h of ischaemic stroke onset or last known well, were not being considered for endovascular thrombectomy, and met target mismatch criteria on brain perfusion imaging. Patients were randomly assigned (1:1) by use of a centralised web server with randomly permuted blocks to intravenous tenecteplase (0·25 mg/kg) or alteplase (0·90 mg/kg). The primary outcome was the proportion of patients without disability (modified Rankin Scale 0-1) at 3 months, assessed via masked review in both the intention-to-treat and per-protocol populations. We aimed to recruit 832 participants to yield 90% power (one-sided alpha=0·025) to detect a risk difference of 0·08, with an absolute non-inferiority margin of -0·03. The trial was registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000243718, and the European Union Clinical Trials Register, EudraCT Number 2015-002657-36, and it is completed. FINDINGS: Recruitment ceased early following the announcement of other trial results showing non-inferiority of tenecteplase versus alteplase. Between March 21, 2014, and Oct 20, 2023, 680 patients were enrolled and randomly assigned to tenecteplase (n=339) and alteplase (n=341), all of whom were included in the intention-to-treat analysis (multiple imputation was used to account for missing primary outcome data for five patients). Protocol violations occurred in 74 participants, thus the per-protocol population comprised 601 people (295 in the tenecteplase group and 306 in the alteplase group). Participants had a median age of 74 years (IQR 63-82), baseline National Institutes of Health Stroke Scale score of 7 (4-11), and 260 (38%) were female. In the intention-to-treat analysis, the primary outcome occurred in 191 (57%) of 335 participants allocated to tenecteplase and 188 (55%) of 340 participants allocated to alteplase (standardised risk difference [SRD]=0·03 [95% CI -0·033 to 0·10], one-tailed pnon-inferiority=0·031). In the per-protocol analysis, the primary outcome occurred in 173 (59%) of 295 participants allocated to tenecteplase and 171 (56%) of 306 participants allocated to alteplase (SRD 0·05 [-0·02 to 0·12], one-tailed pnon-inferiority=0·01). Nine (3%) of 337 patients in the tenecteplase group and six (2%) of 340 in the alteplase group had symptomatic intracranial haemorrhage (unadjusted risk difference=0·01 [95% CI -0·01 to 0·03]) and 23 (7%) of 335 and 15 (4%) of 340 died within 90 days of starting treatment (SRD 0·02 [95% CI -0·02 to 0·05]). INTERPRETATION: The findings in our study provide further evidence to strengthen the assertion of the non-inferiority of tenecteplase to alteplase, specifically when perfusion imaging has been used to identify reperfusion-eligible stroke patients. Although non-inferiority was achieved in the per-protocol population, it was not reached in the intention-to-treat analysis, possibly due to sample size limtations. Nonetheless, large-scale implementation of perfusion CT to assist in patient selection for intravenous thrombolysis in the early time window was shown to be feasible. FUNDING: Australian National Health Medical Research Council; Boehringer Ingelheim.
引用
- Parsons MW, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024. PMID: 38880118. doi:10.1016/S1474-4422(24)00206-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。